Acquisition of resistant bowel flora during a double-blind randomized clinical trial of ertapenem versus piperacillin-tazobactam therapy for intraabdominal infections

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 8, 2005, Pages 3217-3221

  DiNubile, Mark J ^a   Chow, Joseph W ^a   Satishchandran, Vilas ^a   Polis, Adam ^a   Motyl, Mary R ^a   Abramson, Murray A ^a   Teppler, Hedy ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERTAPENEM; PIPERACILLIN PLUS TAZOBACTAM;

ABDOMINAL INFECTION; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL COLONIZATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENTEROBACTERIACEAE; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; FEMALE; HUMAN; INTESTINE FLORA; KLEBSIELLA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ABDOMINAL ABSCESS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BETA-LACTAMS; DOUBLE-BLIND METHOD; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; ENTEROBACTERIACEAE; FEMALE; HUMANS; LACTAMS; MALE; MIDDLE AGED; PENICILLANIC ACID; PIPERACILLIN; RECTUM; TREATMENT OUTCOME;

EID: 23044480845     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.8.3217-3221.2005     Document Type: Article

References (29)

1. Bhalla, A., N. J. Pultz, A. J. Ray, C. K. Hoyen, E. C. Eckstein, and C. J. Donskey. 2003. Antianaerobic antibiotic therapy promotes overgrowth of antibiotic-resistant, gram-negative bacilli and vancomycin-resistant enterococci in the stool of colonized patients. Infect. Control Hosp. Epidemiol. 24:644-649.
2. Cosgrove, S. E., K. S. Kaye, G. M. Eliopoulous, and Y. Carmeli. 2002. Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species. Arch. Intern. Med. 162:185-190.
3. D'Agata, E. M., S. Gautam, W. K. Green, and Y. W. Tang. 2002. High rate of false-negative results of the rectal swab culture method in detection of gastrointestinal colonization with vancomycin-resistant enterococci. Clin. Infect. Dis. 34:167-172.
4. Donskey, C. J. 2004. The role of the intestinal tract as a reservoir and source for transmission of nosocomial pathogens. Clin. Infect. Dis. 39:219-226.
5. Donskey, C. J., T. K. Chowdhry, M. T. Hecker, C. K. Hoyen, J. A. Hanrahan, A. M. Hujer, R. A. Hutton-Thomas, C. C. Whalen, R. A. Bonomo, and L. B. Rice. 2000. Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. N. Engl. J. Med. 343:1925-1932.
6. Friedland, L., C. Chan, H. Giezek, M. Motyl, G. Woods, and M. Shivaprakash. 2003. Isolation of resistant faecal enterics in patients treated with piperacillin-tazobactam vs. ertapenem. 13th Eur. Cong. Clin. Microbiol. Infect. Dis., Glasgow, United Kingdom, 10-13 May 2003.
7. Friedland, I., M. Shivaprakash, H. Giezek, M. Motyl, M. DiNubile, and C. Chan. 2003. Emergence of resistant gram-negative bacilli in the bowel of patients treated with ceftriaxone/metronidazole vs. ertapenem for intraabdominal infections. 3rd Int. Meet. Antimicrob. Chemother. Clin. Pract. (ACCP), Portofino, Genoa, Italy, October 2003.
8. Harbarth, S., S. Cosgrove, and Y. Carmeli. 2002. Effects of antibiotics on nosocomial epidemiology of vancomycin-resistant enterococci. Antimicrob Agents Chemother. 46:1619-1628.
9. Hoyen, C. K., N. J. Pultz, D. L. Paterson, D. C. Aron, and C. J. Donskey. 2003. Effect of parenteral antibiotic administration on establishment of intestinal colonization in mice by Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases. Antimicrob. Agents Chemother. 47:3610-3612.
10. Kollef, M. H., G. Sherman, S. Ward, and V. J. Fraser. 1999. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 115:462-474.
11. Lautenbach, E., A. D. Harris, E. N. Perencevich, I. Nachamkin, P. Tolomeo, and J. P. Metlay. 2005. Test characteristics of perirectal and rectal swab compared to stool sample for detection of fluoroquinolone-resistant Escherichia coli in the gastrointestinal tract. Antimicrob. Agents Chemother. 49: 798-800.
12. Leonard, F., A. Andremont, B. Leclerq, R. Labia, and C. Tancrede. 1989. Use of beta-lactamase-producing anaerobes to prevent ceftriaxone from degrading intestinal resistance to colonization. J. Infect. Dis. 160:274-280.
13. Livermore, D. M. 2002. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin. Infect. Dis. 34:634-640.
14. Namias, N., E. Jensen, T. King, S. Knight, S. Rawlins, and M. Abramson. 2005. Efficacy, safety, and tolerabiliry of intravenous (IV) ertapenem (E) vs. piperacillin/tazobactam (P/T) in the treatment of complicated intra-abdominal infections in hospitalized adults. 25th Ann. Meet. SIS and 2nd Joint Meet. SIS-E, 5-7 May 2005, Miami, Fla.
15. National Committee for Clinical Laboratory Standards. 2001. Performance standards for antimicrobial susceptibility testing, 11th informational supplement, vol. 21. National Committee for Clinical Laboratory Standards, Wayne, Pa.
16. Ostrowsky, B. E., W. E. Trick, A. H. Sohn, S. B. Quirk, S. Holt, L. A. Carson, B. C. Hill, M. J. Arduino, M. J. Kuehnert, and W. R. Jarvis. 2001. Control of vancomycin-resistant enterococcus in health care facilities in a region. N. Engl. J. Med. 344:1427-1433.
17. Ostrowsky, B. E., L. Venkataraman, E. M. D'Agata, H. S. Gold, P. C. DeGirolami, and M. H. Samore. 1999. Vancomycin-resistant enterococci in intensive care units: high frequency of stool carriage during a non-outbreak period. Arch. Intern. Med. 159:1467-1472.
18. Paterson, D. L. 2004. "Collateral damage" from cephalosporin or quinolone antibiotic therapy. Clin. Infect. Dis. 38(Suppl. 4):S341-S345.
19. Paterson, D. L., W. C. Ko, A. Von Gottberg, J. M. Casellas, L. Mulazimoglu, K. P. Klugman, R. A. Bonomo, L. B. Rice, J. G. McCormack, and V. L. Yu. 2001. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J. Clin. Microbiol. 39:2206-2212.
20. Paterson, D. L., W. C. Ko, A. Von Gottberg, S. Mohapatra, J. M. Casellas, H. Goossens, L. Mulazimoglu, G. Trenholme, K. P. Klugman, R. A. Bonomo, L. B. Rice, M. M. Wagener, J. G. McCormack, and V. L. Yu. 2004. International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial infections. Ann. Intern. Med. 140:26-32.
21. Piroth, L., H. Aube, J. M. Doise, and M. Vincent-Martin. 1998. Spread of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae: are beta-lactamase inhibitors of therapeutic value? Clin. Infect. Dis. 27:76-80.
22. Pletz, M. W. R., M. Rau, J. Bulitta, A. De Roux, O. Burkhardt, G. Kruse, M. Kurowski, C. E. Nord, and H. Lode. 2004. Ertapenem pharmacokinetics and impact on intestinal microflora, in comparison to those of ceftriaxone, after multiple dosing in male and female volunteers. Antimicrob. Agents Chemother. 48:3765-3772.
23. Safdar, N., and D. G. Maki. 2002. The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, enterococcus, gram-negative bacilli, Clostridium difficile, and Candida. Ann. Intern. Med. 136:834-844.
24. Shah, P. M., and R. D. Isaacs. 2003. Ertapenem, the first of a new group of carbapenems. J. Antimicrob. Chemother. 52:538-542.
25. Solomkin, J. S., A. E. Yellin, O. D. Rotstein, N. V. Christou, E. P. Dellinger, J. M. Tellado, O. Malafaia, A. Fernandez, K. A. Choe, A. Carides, V. Satishchandran, and H. Teppler. 2003. Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial. Ann. Surg. 237: 235-245.
26. Stiefel, U., D. L. Paterson, N. J. Pultz, S. M. Gordon, D. C. Aron, and C. J. Donskey. 2004. Effect of the increasing use of piperacillin/tazobactam on the incidence of vancomycin-resistant enterococci in four academic medical centers. Infect. Control Hosp. Epidemiol. 25:380-383.
27. Stiefel, U., N. J. Pultz, M. S. Helfand, and C. J. Donskey. 2004. Increased susceptibility to vancomycin-resistant Enterococcus intestinal colonization persists after completion of anti-anaerobic antibiotic treatment in mice. Infect. Control Hosp. Epidemiol. 25:373-379.
28. Trouillet, J. L., A. Vuagnat, A. Combes, N. Kassis, J. Chastre, and C. Gibert. 2002. Pseudomonas aeruginosa ventilator-associated pneumonia: comparison of episodes due to piperacillin-resistant versus piperacillin-susceptible organisms. Clin. Infect. Dis. 34:1047-1054.
29. Weinstein, J. W., S. Tallapragada, P. Farrel, and L. M. Dembry. 1996. Comparison of rectal and perirectal swabs for detection of colonization with vancomycin-resistant enterococci. J. Clin. Microbiol. 34:210-212.